CS417791A3 - Capsules or tablets with a controlled release - Google Patents

Capsules or tablets with a controlled release Download PDF

Info

Publication number
CS417791A3
CS417791A3 CS914177A CS417791A CS417791A3 CS 417791 A3 CS417791 A3 CS 417791A3 CS 914177 A CS914177 A CS 914177A CS 417791 A CS417791 A CS 417791A CS 417791 A3 CS417791 A3 CS 417791A3
Authority
CS
Czechoslovakia
Prior art keywords
polyvinylpyrrolidone
weight
dihydropyridine
polymer
sustained release
Prior art date
Application number
CS914177A
Other languages
Czech (cs)
English (en)
Inventor
Seamus Mulligan
Randall T Sparks
Original Assignee
Elan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp filed Critical Elan Corp
Publication of CS417791A3 publication Critical patent/CS417791A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CS914177A 1987-01-09 1991-12-30 Capsules or tablets with a controlled release CS417791A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE6487A IE59540B1 (en) 1987-01-09 1987-01-09 Sustained release capsule or tablet formulation

Publications (1)

Publication Number Publication Date
CS417791A3 true CS417791A3 (en) 1992-06-17

Family

ID=11006244

Family Applications (1)

Application Number Title Priority Date Filing Date
CS914177A CS417791A3 (en) 1987-01-09 1991-12-30 Capsules or tablets with a controlled release

Country Status (12)

Country Link
EP (1) EP0274176B1 (da)
JP (1) JP2763879B2 (da)
AU (1) AU592618B2 (da)
CA (1) CA1288049C (da)
CS (1) CS417791A3 (da)
DE (1) DE3779414D1 (da)
DK (1) DK172893B1 (da)
ES (1) ES2042547T3 (da)
IE (1) IE59540B1 (da)
NZ (1) NZ219140A (da)
PH (1) PH23528A (da)
ZA (1) ZA87738B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2880021A (en) * 1954-03-12 1959-03-31 Herbert E White Telescopic pipe joint with tolerance accommodating means
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
IE60458B1 (en) * 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
ATE135214T1 (de) * 1992-02-17 1996-03-15 Siegfried Ag Pharma Darreichungsformen mit verlaengerter wirkstoffreigabe
WO1994005262A1 (en) * 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
CN1082811C (zh) * 1995-03-29 2002-04-17 盐野义制药株式会社 具有调节水活性的明胶胶囊
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
IN186245B (da) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
ATE391495T1 (de) 1999-09-30 2008-04-15 Penwest Pharmaceuticals Co Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
KR100396443B1 (ko) * 2001-09-08 2003-09-02 한국유나이티드제약 주식회사 가용화된 펠로디핀 함유 지속성제제의 조성물 및 그의제조방법
WO2005023225A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Cilostazol adsorbate
CN101103964B (zh) * 2006-07-14 2010-09-29 海南盛科生命科学研究院 一种含有非洛地平的缓释制剂及其制备方法
IE20100799A1 (en) * 2010-12-22 2012-08-01 Eurand Pharmaceuticals Ltd Pharmaceutical composites of poorly water soluble drugs and polymers
CN102188401B (zh) * 2011-05-10 2013-07-03 山东威高药业有限公司 一种非洛地平缓释片及其制备方法
CN104758938B (zh) * 2015-04-01 2017-08-29 新乡医学院第一附属医院 一种治疗高血压的非洛地平片剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA765931B (en) * 1975-10-10 1977-09-28 Squibb & Sons Inc Controlled release tablet
JPS5446837A (en) * 1977-09-19 1979-04-13 Kanebo Ltd Easily absorbable nifedipin composition, its preparation, and anti-stenocardia containing the same
DE3006635A1 (de) * 1980-02-22 1981-08-27 Basf Ag, 6700 Ludwigshafen Verwendung von mikronisiertem vernetztem, unloeslichem polyvinylpyrrolidon zur stabilisierung von suspensionen
EP0078430B2 (de) * 1981-10-29 1993-02-10 Bayer Ag Verfahren zur Herstellung von festen, schnellfreisetzenden Arzneizubereitungen mit Dihydropyridinen
DE3427402A1 (de) * 1984-07-25 1986-01-30 Bayer Ag, 5090 Leverkusen Neues kombinationspraeparat, verfahren zu seiner herstellung und seine verwendung als arzneimittel
JPS618A (ja) * 1984-06-09 1986-01-06 Sawai Seiyaku Kk ニフエジピン含有製剤
JPS6115829A (ja) * 1984-06-29 1986-01-23 Toyobo Co Ltd 口腔粘膜適用徐放性ニフエジピン製剤
JPS6117510A (ja) * 1984-07-03 1986-01-25 Toyobo Co Ltd 口腔粘膜適用徐放性ニフエジピン製剤
DE3424553A1 (de) * 1984-07-04 1986-01-09 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system

Also Published As

Publication number Publication date
DK52887A (da) 1988-07-10
NZ219140A (en) 1989-03-29
AU592618B2 (en) 1990-01-18
ZA87738B (en) 1987-09-30
EP0274176A2 (en) 1988-07-13
DE3779414D1 (de) 1992-07-02
PH23528A (en) 1989-08-25
DK52887D0 (da) 1987-02-02
IE870064L (en) 1988-07-09
IE59540B1 (en) 1994-03-09
ES2042547T3 (es) 1993-12-16
DK172893B1 (da) 1999-09-20
EP0274176A3 (en) 1988-09-14
JP2763879B2 (ja) 1998-06-11
CA1288049C (en) 1991-08-27
JPS63174929A (ja) 1988-07-19
AU6820787A (en) 1988-07-14
EP0274176B1 (en) 1992-05-27

Similar Documents

Publication Publication Date Title
US5015479A (en) Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
CS417791A3 (en) Capsules or tablets with a controlled release
US4404183A (en) Sustained release pharmaceutical composition of solid medical material
DK173082B1 (da) Præparat til forsinket frigivelse af et lægemiddel fra et Matrix-System
US5900425A (en) Pharmaceutical preparations having controlled release of active compound and processes for their preparation
EP0218148B1 (en) Slow-release pharmaceutical composition
SK153497A3 (en) Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
CA2207084A1 (en) Controlled release matrix for pharmaceuticals
EA006103B1 (ru) Лекарственная форма парацетамола
HU197844B (en) Process for producing solid pharmaceutical compositions comprising dihydropyridine derivatives
KR20050082038A (ko) 탐수로신 염산염의 경구투여용 조성물 및 이의 서방성과립 제제
EP0410422A2 (en) A highly absorbable pharmaceutical composition
JPH04210638A (ja) 流体形態で経口投与するための医薬調製物
WO2015011161A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
JPH029007B2 (da)
JPH08301789A (ja) 活性化合物の調節された放出性を有する製剤およびそれらの製造方法
JPS625915A (ja) 塩酸ジルチアゼム徐放性製剤及びその製法
EP4076453B1 (en) A pharmaceutical oral dosage form of q203
KR100647901B1 (ko) 세파클러-함유 서방성 약제조성물 및 그의 제조방법
JPS63243030A (ja) 持効性セフラジン製剤
MX2007013493A (es) Composicion que contiene farmaco antidemencia.